Kidney issues, access to innovation, rare disease issues, organ rejection
2025 · 4th Quarter (Oct 1 - Dec 31)
HANSA BIOPHARMA
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- HANSA BIOPHARMA
- Filing UUID
- b2c10f28-7bf6-4190-b90d-07d34d424dc4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Federal budget issues
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.